Jove
Visualize
Contact Us

Related Experiment Video

Updated: Aug 16, 2025

Monitoring of Nanodrug Accumulation in Murine Breast Cancer Metastases
09:48

Monitoring of Nanodrug Accumulation in Murine Breast Cancer Metastases

Published on: August 23, 2024

421

Synthetic miR-34a against solid tumours: a predictable failure.

Sophie Mockly1,2, Hervé Seitz3

  • 1Institut de Génétique Humaine, UMR 9002 CNRS and university of Montpellier, Montpellier, France.

British Journal of Cancer
|December 22, 2022
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

TopBP1 biomolecular condensates as a new therapeutic target in advanced-stage colorectal cancer.

eLife·2025
Same author

[Nobel Prize in physiology or medicine 2024: Victor Ambros and Gary Ruvkun - The discovery of microRNAs, revealing a New World in genetics].

Medecine sciences : M/S·2025
Same author

A new perspective on microRNA-guided gene regulation specificity, and its potential generalization to transcription factors and RNA-binding proteins.

Nucleic acids research·2024
Same author

Looking for a needle in a haystack: de novo phenotypic target identification reveals Hippo pathway-mediated miR-202 regulation of egg production.

Nucleic acids research·2023
Same author

Biochemistry-informed design selects potent siRNAs against SARS-CoV-2.

RNA biology·2023
Same author

A rationalized definition of general tumor suppressor microRNAs excludes miR-34a.

Nucleic acids research·2022
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Many microRNAs (miRNAs) show promise as cancer treatments, but flawed analyses often lead to failure. The miR-34a clinical trial

Area of Science:

  • Oncology
  • Molecular Biology
  • Biochemistry

Background:

  • MicroRNAs (miRNAs) are implicated in cancer, with many studied for therapeutic potential.
  • miR-34a was identified as a potential tumor suppressor miRNA.
  • A clinical trial involving miR-34a yielded disappointing results.

Approach:

  • Reviewing scientific literature on miRNA functions in cancer.
  • Analyzing the reasons behind the failure of the miR-34a clinical trial.
  • Evaluating the implications for future miRNA-based cancer therapies.

Key Points:

  • Numerous studies attribute oncogenic or tumor-suppressive roles to miRNAs based on weak evidence.
  • The clinical trial of miR-34a, a candidate tumor suppressor miRNA, did not meet expectations.

More Related Videos

Predictive Immune Modeling of Solid Tumors
08:50

Predictive Immune Modeling of Solid Tumors

Published on: February 25, 2020

7.0K
In Vivo Inhibition of MicroRNA to Decrease Tumor Growth in Mice
07:02

In Vivo Inhibition of MicroRNA to Decrease Tumor Growth in Mice

Published on: August 23, 2019

7.4K

Related Experiment Videos

Last Updated: Aug 16, 2025

Monitoring of Nanodrug Accumulation in Murine Breast Cancer Metastases
09:48

Monitoring of Nanodrug Accumulation in Murine Breast Cancer Metastases

Published on: August 23, 2024

421
Predictive Immune Modeling of Solid Tumors
08:50

Predictive Immune Modeling of Solid Tumors

Published on: February 25, 2020

7.0K
In Vivo Inhibition of MicroRNA to Decrease Tumor Growth in Mice
07:02

In Vivo Inhibition of MicroRNA to Decrease Tumor Growth in Mice

Published on: August 23, 2019

7.4K
  • Flawed analytical methodologies in preclinical research may explain therapeutic failures.

    • Conclusions:

    • The promising therapeutic potential of miRNAs in oncology requires rigorous validation.
    • Re-evaluation of analytical approaches is crucial for advancing miRNA-based cancer treatments.
    • Lessons learned from miR-34a failure can guide future miRNA research and clinical applications.